Skip to main
VNRX
VNRX logo

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX Ltd demonstrated a positive financial trajectory with a 32% year-over-year increase in revenue, reaching $0.6 million, which suggests robust demand for its diagnostic services. The company’s strategic partnerships, including with a major European cancer center and agreements with Werfen and Hologic, enhance its market position and expand its customer base, paving the way for potential revenue growth through upfront and milestone payments as well as recurring royalties. Furthermore, a reduction in net loss by 8% and a 33% decrease in cash used in operating activities underscore efficient cost management, positioning VolitionRX favorably for future profitability as it seeks to scale its innovative diagnostic solutions.

Bears say

VolitionRX Ltd has seen a decline in operating expenses, which is a positive indicator, with a 10% reduction for the quarter and an 18% year-to-date decrease. However, the company faces significant risks that could negatively impact its financial performance, including potential failures in clinical development and challenges in securing license agreements and market traction for its diagnostic products. Additionally, concerns around dilution risk, going concern, and potential delisting present substantial threats to investor confidence and valuation.

Volitionrx Limited (VNRX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.